Product Description: Rubitecan (RFS 2000), a Camptothecin derivative, is an orally active topoisomerase I inhibitor with broad antitumor activity, and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells[1][2][3].
Applications: Cancer-programmed cell death
Formula: C20H15N3O6
References: [1]Burris HA 3rd, et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist. 2005 Mar;10(3):183-90./[2]Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000. Drugs R D. 2004;5(5):305-11./[3]Rubitecan/[4]Xia M, et al. Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther. 2013 Jul;14(7):638-47.
CAS Number: 91421-42-0
Molecular Weight: 393.35
Compound Purity: 99.23
Research Area: Cancer
Solubility: DMSO : 62.5 mg/mL (ultrasonic)
Target: Topoisomerase
English
Deutsch
